Volume 6, Issue 1, February 2018, Page: 22-28
Regulation of Osteoblastic Differentiation: A Concept Note
Poonam Kanta, Department of Virology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Dheeraj Dumir, Department of Cardiology, Max Super speciality Hospital, Mohali, Punjab, India
Alka Khera, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Received: Jun. 25, 2018;       Published: Jun. 26, 2018
DOI: 10.11648/j.ajls.20180601.14      View  700      Downloads  43
Abstract
Bone is endocrine metabolic organ which maintains its integrity through the process of bone remodeling controlled by several local and systemic factors. Any perturbation in the bone remodeling leads to development of osteoporosis which is mostly age related but can be premature as well. Several therapies have come up to treat osteoporosis including bisphosphonates but due to side effects natural compounds are looked like resveratrol which has estrogenic property depending upon the type of tissue it is acting upon. Resveratrol has stimulatory effect on bone cells by modulating the process of differentiation through change in the expression levels of osteoblastic genes through estrogen receptors.
Keywords
Bone Remodeling, Osteoporosis, Phytoestrogen, Resveratrol
To cite this article
Poonam Kanta, Dheeraj Dumir, Alka Khera, Regulation of Osteoblastic Differentiation: A Concept Note, American Journal of Life Sciences. Vol. 6, No. 1, 2018, pp. 22-28. doi: 10.11648/j.ajls.20180601.14
Reference
[1]
Manolagas, S. C., C. A. O'Brien, and M. Almeida, "The role of estrogen and androgen receptors in bone health and disease." Nat Rev Endocrinol, 2013. 9(12): p. 699-712.
[2]
Crockett, J. C., et al., "Bone remodelling at a glance." J Cell Sci, 2011. 124(Pt 7): p. 991-8.
[3]
Almeida, M., et al., "Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual." J Clin Invest, 2013. 123(1): p. 394-404.
[4]
Syed, F. A., et al., "Distinct effects of loss of classical estrogen receptor signaling versus complete deletion of estrogen receptor alpha on bone." Bone, 2011. 49(2): p. 208-16.
[5]
Compston, J. E., "Sex steroids and bone." Physiol Rev, 2001. 81(1): p. 419-447.
[6]
Nasu, M., et al., "Estrogen modulates osteoblast proliferation and function regulated by parathyroid hormone in osteoblastic saos-2 cells: Role of insulin-like growth factor (igf)-i and igf-binding protein-5." J Endocrinol, 2000. 167(2): p. 305-13.
[7]
Rossini, M., et al., "Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture." Drug Des Devel Ther, 2013. 7: p. 601-10.
[8]
Lagari, V. S. and S. Levis, "Phytoestrogens in the prevention of postmenopausal bone loss." J Clin Densitom, 2013. 16(4): p. 445-9.
[9]
Wardlaw, G. M., "Putting osteoporosis in perspective." J Am Diet Assoc, 1993. 93(9): p. 1000-6.
[10]
Sugimoto, E. and M. Yamaguchi, "Stimulatory effect of daidzein in osteoblastic mc3t3-e1 cells." Biochem Pharmacol, 2000. 59(5): p. 471-5.
[11]
Blair, H. C., et al., "Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats." J Cell Biochem, 1996. 61(4): p. 629-37.
[12]
Arjmandi, B. H., et al., "Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis." J Nutr, 1996. 126(1): p. 161-7.
[13]
Arjmandi, B. H., et al., "Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats." Am J Clin Nutr, 1998. 68(6 Suppl): p. 1358S-1363S.
[14]
Pilsakova, L., I. Riecansky, and F. Jagla, "The physiological actions of isoflavone phytoestrogens." Physiol Res, 2010. 59(5): p. 651-64.
[15]
Rucinski, M., et al., "Estradiol and resveratrol stimulating effect on osteocalcin, but not osteonectin and collagen-1alpha gene expression in primary culture of rat calvarial osteoblast-like cells." Int J Mol Med, 2006. 18(4): p. 565-70.
[16]
Zainabadi, K., C. J. Liu, and L. Guarente, "Sirt1 is a positive regulator of the master osteoblast transcription factor, runx2." PLoS One, 2017. 12(5): p. e0178520.
[17]
Tseng, P. C., et al., "Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating runx2 gene expression via the sirt1/foxo3a axis." J Bone Miner Res, 2011. 26(10): p. 2552-63.
[18]
Dai, Z., et al., "Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via er-dependent erk1/2 activation." Phytomedicine, 2007. 14(12): p. 806-14.
[19]
Erdman, C. P., et al., "Effects of resveratrol on enrichment of adipose-derived stem cells and their differentiation to osteoblasts in two-and three-dimensional cultures." J Tissue Eng Regen Med, 2012. 6 Suppl 3: p. s34-46.
[20]
Mizutani, K., et al., "Resveratrol stimulates the proliferation and differentiation of osteoblastic mc3t3-e1 cells." Biochem Biophys Res Commun, 1998. 253(3): p. 859-63.
[21]
Liu, Z. P., et al., "Effects of trans-resveratrol from polygonum cuspidatum on bone loss using the ovariectomized rat model." J Med Food, 2005. 8(1): p. 14-9.
[22]
Xi, H., et al., "[effect of resveratrol on peak bone mass in growing rats]." Zhejiang Da Xue Xue Bao Yi Xue Ban, 2017. 46(6): p. 578-584.
[23]
Bagchi, D., et al., "Benefits of resveratrol in women's health." Drugs Exp Clin Res, 2001. 27(5-6): p. 233-48.
[24]
Matsuda, Y., et al., "Resveratrol suppresses the alveolar bone resorption induced by artificial trauma from occlusion in mice." Oral Dis, 2018. 24(3): p. 412-421.
[25]
Gehm, B. D., et al., "Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor." Proc Natl Acad Sci U S A, 1997. 94(25): p. 14138-43.
[26]
Basly, J. P., et al., "Estrogenic/antiestrogenic and scavenging properties of (e)- and (z)-resveratrol." Life Sci, 2000. 66(9): p. 769-77.
[27]
Bowers, J. L., et al., "Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta." Endocrinology, 2000. 141(10): p. 3657-67.
[28]
Bhat, K. P., et al., "Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models." Cancer Res, 2001. 61(20): p. 7456-63.
[29]
Bhat, K. P. and J. M. Pezzuto, "Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (ishikawa) cells." Cancer Res, 2001. 61(16): p. 6137-44.
[30]
Chakraborty, S., A. S. Levenson, and P. K. Biswas, "Structural insights into resveratrol's antagonist and partial agonist actions on estrogen receptor alpha." BMC Struct Biol, 2013. 13: p. 27.
[31]
Martins, M. J., M. R. Negrao, and C. Hipolito-Reis, "Alkaline phosphatase from rat liver and kidney is differentially modulated." Clin Biochem, 2001. 34(6): p. 463-8.
[32]
Raisz, L. G., "The osteoporosis revolution marches on." J Orthop Sci, 2007. 12(4): p. 405-12.
[33]
Bonnelye, E. and J. E. Aubin, "Differential expression of estrogen receptor-related receptor alpha and estrogen receptors alpha and beta in osteoblasts in vivo and in vitro." J Bone Miner Res, 2002. 17(8): p. 1392-400.
[34]
Golub, E. E. and K. Boesze-Battaglia, "The role of alkaline phosphatase in mineralization." Current Opinion in Orthopaedics, 2007. 18(5): p. 444-448.
[35]
Rao, L. G., et al., "Estrogen added intermittently, but not continuously, stimulates differentiation and bone formation in saos-2 cells." Biol Pharm Bull, 2003. 26(7): p. 936-45.
[36]
Matsumoto, Y., et al., "Estrogen facilitates osteoblast differentiation by upregulating bone morphogenetic protein-4 signaling." Steroids, 2013. 78(5): p. 513-20.
[37]
Wei, A., et al., "Bmp-7 in combination with estrogen enhances bone formation in a fracture callus explant culture." Tohoku J Exp Med, 2010. 221(1): p. 61-8.
[38]
Parikka, V., et al., "Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice." Eur J Endocrinol, 2005. 152(2): p. 301-14.
[39]
Monroe, D. G., et al., "Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either eralpha or erbeta." J Cell Biochem, 2003. 90(2): p. 315-26.
[40]
Guntur, A. R. and C. J. Rosen, "Bone as an endocrine organ." Endocr Pract, 2012. 18(5): p. 758-62.
[41]
Guo, A. J., et al., "Kaempferol as a flavonoid induces osteoblastic differentiation via estrogen receptor signaling." Chin Med, 2012. 7: p. 10.
[42]
Yen, M. L., et al., "Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: A possible in vitro model of human mesenchymal progenitors." Stem Cells, 2007. 25(1): p. 125-31.
[43]
Khalid, O., et al., "Modulation of runx2 activity by estrogen receptor-alpha: Implications for osteoporosis and breast cancer." Endocrinology, 2008. 149(12): p. 5984-95.
[44]
Cao, Y., et al., "Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma." Cancer Res, 2005. 65(4): p. 1124-8.
[45]
Zhu, F., et al., "The transcription factor osterix (sp7) regulates bmp6-induced human osteoblast differentiation." J Cell Physiol, 2012. 227(6): p. 2677-85.
[46]
Kim, J. H., et al., "Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk." Lung Cancer, 2007. 56(1): p. 9-15.
[47]
Wejheden, C., et al., "Osteopontin: A rapid and sensitive response to dioxin exposure in the osteoblastic cell line umr-106." Biochem Biophys Res Commun, 2006. 341(1): p. 116-20.
[48]
Lee, L. L., et al., "Polycyclic aromatic hydrocarbons present in cigarette smoke cause bone loss in an ovariectomized rat model." Bone, 2002. 30(6): p. 917-23.
[49]
Yun, C., et al., "Aryl hydrocarbon receptor antagonists mitigate the effects of dioxin on critical cellular functions in differentiating human osteoblast-like cells." Int J Mol Sci, 2018. 19(1).
[50]
Singh, S. U., et al., "Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol." J Endocrinol, 2000. 167(1): p. 183-95.
[51]
Ohtake, F., et al., "Modulation of oestrogen receptor signalling by association with the activated dioxin receptor." Nature, 2003. 423(6939): p. 545-50.
[52]
Schlezinger, J. J., et al., "A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis." Biol Chem, 2006. 387(9): p. 1175-87.
[53]
Li, F. and C. Niyibizi, "Cells derived from murine induced pluripotent stem cells (ipsc) by treatment with members of tgf-beta family give rise to osteoblasts differentiation and form bone in vivo." BMC Cell Biol, 2012. 13: p. 35.
[54]
Ehnert, S., et al., "Tgf-beta1 as possible link between loss of bone mineral density and chronic inflammation." PLoS One, 2010. 5(11): p. e14073.
[55]
Sun, P., et al., "Bmp2/7 heterodimer is a stronger inducer of bone regeneration in peri-implant bone defects model than bmp2 or bmp7 homodimer." Dent Mater J, 2012. 31(2): p. 239-48.
[56]
Zhou, S., et al., "Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells." Mol Endocrinol, 2003. 17(1): p. 56-66.
[57]
Jang, W. G., et al., "Bmp2 protein regulates osteocalcin expression via runx2-mediated atf6 gene transcription." J Biol Chem, 2012. 287(2): p. 905-15.
[58]
Hyzy, S. L., et al., "Bmp2 induces osteoblast apoptosis in a maturation state and noggin-dependent manner." J Cell Biochem, 2012. 113(10): p. 3236-45.
[59]
McBride, S. H., et al., "Long bone structure and strength depend on bmp2 from osteoblasts and osteocytes, but not vascular endothelial cells." PLoS One, 2014. 9(5): p. e96862.
[60]
Phillips, F. M., et al., "In vivo bmp-7 (op-1) enhancement of osteoporotic vertebral bodies in an ovine model." Spine J, 2006. 6(5): p. 500-6.
Browse journals by subject